Flex Pharma Inc Cmn (FLKS) 11.49 $FLKS Flex Pharma

New Post Public Reply Private Reply Replies (0) Message Board

Sep 23, 2016 at 7:05 AM

Flex Pharma Inc Cmn (FLKS) 11.49 $FLKS

Flex Pharma Initiates Phase 2 Efficacy Study in Amyotrophic Lateral Sclerosis
BusinessWire - Tue Sep 13, 6:30AM CDT
Click to Tweet this News
FLKS: 11.49 (+0.16)

Flex Pharma Presenting at Upcoming Investor Conferences in September 2016
BusinessWire - Thu Sep 01, 7:30AM CDT
Click to Tweet
FLKS: 11.49 (+0.16)

Flex Pharma Announces Scientific Advisory Board Appointment and Management Change
BusinessWire - Fri Aug 26, 3:05PM CDT
-- Kathie Lindemann, COO, Continues Leading Consumer; Marina Hahn Transitions to Advisor --
FLKS: 11.49 (+0.16)

Flex Pharma Reports Second Quarter 2016 Financial Results
BusinessWire - Wed Aug 03, 6:00AM CDT
-- Phase 2 MS Study of FLX-787 Initiated in June; Phase 2 ALS Study to Start in the Coming Months --
FLKS: 11.49 (+0.16)

Flex Pharma Presenting at Upcoming Investor Conferences in June 2016
BusinessWire - Fri Jun 03, 7:00AM CDT
Click to Tweet
FLKS: 11.49 (+0.16)

Scientific Breakthrough In Sports Nutrition To Change The Game For Millions Of Endurance Athletes
PR Newswire - Thu Jun 02, 7:00AM CDT
Exercise-associated muscle cramps are agonizing. Millions of athletes and fitness enthusiasts suffer from them - even the best trained and most nutritionally-savvy. They're painful, unpredictable and can rob an athlete of a killer performance and confidence. Existing "remedies" that target the muscle have limited scientific evidence that they work.
FLKS: 11.49 (+0.16)

Flex Pharma Launches First Consumer Product Scientifically Proven to Prevent and Treat Muscle Cramps
BusinessWire - Thu Jun 02, 6:30AM CDT
Flex Pharma, Inc. (NASDAQ: FLKS):
FLKS: 11.49 (+0.16)

Flex Pharma Initiates Human Efficacy Study with Single Molecule Tablet in Nocturnal Leg Cramps
BusinessWire - Wed May 25, 7:00AM CDT
Click to Tweet this News
FLKS: 11.49 (+0.16)

Flex Pharma reports 1Q loss
Automated Insights - Wed May 04, 6:16AM CDT
BOSTON (AP) _ Flex Pharma Inc. (FLKS) on Wednesday reported a loss of $9.6 million in its first quarter.
FLKS: 11.49 (+0.16)

Flex Pharma Reports First Quarter 2016 Financial Results
BusinessWire - Wed May 04, 6:00AM CDT
-- Launching First Consumer Product Scientifically Proven to Treat and Prevent Muscle Cramps --
FLKS: 11.49 (+0.16)

Flex Pharma to Report First Quarter 2016 Results on May 4, 2016
BusinessWire - Wed Apr 27, 7:00AM CDT
Click to Tweet
FLKS: 11.49 (+0.16)

Flex Pharma's Positive Human NLC Study Selected for Presentation at AAN Annual Meeting
BusinessWire - Tue Apr 19, 3:01PM CDT
Click to Tweet
FLKS: 11.49 (+0.16)

Flex Pharma Announces Positive Human Efficacy in Nocturnal Leg Cramp Study
BusinessWire - Tue Feb 02, 6:00AM CST
-- Company to Host Conference Call and Webcast Tuesday Feb 2nd at 9am --
FLKS: 11.49 (+0.16)

The Life Sciences Report's 2016 Small-Cap Biotech Watchlist
Marketwired - Thu Jan 28, 8:02AM CST
This may prove a challenging year for small-cap biotechs, but the five analysts who selected companies for inclusion on The Life Sciences Report's 2016 Small-Cap Biotech Watchlist believe these companies have a good shot at producing innovative products in a variety of indications and producing value for investors. Discovery, it turns out, is not just about finding the cure for a particular disease; it's also about finding the companies best poised to reach that goal.
CRMD: 2.88 (-0.10), AST: 4.75 (+0.24), FLKS: 11.49 (+0.16)

Enrollment Completed in Flex Pharma's Exploratory Human Nocturnal Leg Cramp Study
BusinessWire - Wed Jan 06, 6:00AM CST
Flex Pharma, Inc. (NASDAQ: FLKS):
FLKS: 11.49 (+0.16)

Flex Pharma (FLKS) Looks Good: Stock Adds 5.9% in Session
Zacks Equity Research - Zacks Investment Research - Tue Dec 22, 7:40AM CST
Flex Pharma, Inc. (FLKS) saw its shares rise nearly 6% in the last trading session.
ACHN: 8.44 (+0.34), FLKS: 11.49 (+0.16)

Flex Pharma Added to NASDAQ Biotechnology Index
BusinessWire - Mon Dec 21, 7:00AM CST
Flex Pharma, Inc. (NASDAQ: FLKS):
FLKS: 11.49 (+0.16)

A Change in Tides - Complementary Research on CTI BioPharma, Flex Pharma, Comstock Resources and Tristate Capital Holdings
ACCESSWIRE - Wed Dec 16, 6:31AM CST
NEW YORK, NY / ACCESSWIRE / December 16, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: CTI BioPharma Corp. (NASDAQ: CTIC), Flex Pharma Inc. (NASDAQ: FLKS), Comstock Resources Inc. (NYSE: CRK) and Tristate Capital Holdings Inc. (NASDAQ: TSC). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
TSC: 16.14 (+0.52), CTIC: 0.39 (+0.02), FLKS: 11.49 (+0.16), CRK: 7.16 (-0.12)

Muscle Spasm Global Clinical Trials Review, H2, 2015 - Analysis & Technologies
M2 - Mon Dec 14, 5:59AM CST
Research and Markets (http://www.researchandmarkets.com/research/gsz2s9/muscle_spasm) has announced the addition of the "Muscle Spasm Global Clinical Trials Review, H2, 2015" report to their offering. This clinical trial report, Muscle Spasm Global Clinical Trials Review, H2, 2015" provides an overview of Muscle Spasm clinical trials scenario. This report provides top line data relating to the clinical trials on Muscle Spasm. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. The report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Clinical Trial Reports are generated using Our proprietary database - Pharma eTrack Clinical trials database. Key Topics Covered: - The report provides a snapshot of the global clinical trials landscape - Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status - The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company - The Report provides enrollment trends for the past five years - Report provides latest news for the past three months Benefits of this Report: - Assists in formulating key business strategies with regards to investment - Helps in identifying prominent locations for conducting clinical trials which saves time and cost - Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities - Supports understanding of trials count and enrollment trends by country in global therapeutics market - Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials - Facilitates clinical trial assessment of the indication on a global, regional and country level Companies Mentioned: - Themis Medicare Ltd. - Inventia Healthcare Private Limited - Allergan Plc - Flex Pharma, Inc. - Navipharm Co., Ltd - Meda AB - Ipsen S.A. - Eisai Co., Ltd. - Dr. Reddy's Laboratories Limited - Avigen, Inc. For more information visit http://www.researchandmarkets.com/research/gs...scle_spasm
AGN: 243.43 (+5.02), FLKS: 11.49 (+0.16)

Flex Pharma Presents at the 26th International Symposium on ALS/MND
BusinessWire - Wed Dec 09, 7:00AM CST
Click to Tweet this News
FLKS: 11.49 (+0.16)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Manhattan Associates Faces Investigation by KSF Law Firm

KSF Digs Into Manhattan Associates' Claims In the swirl of the financial world, you rarely see an investigation that doesn’t raise a few eyebrows. This time, it's Manhattan Associates, Inc. (NasdaqGS: MANH) squarely in the crosshairs of Kahn Swick & Foti, LLC (KSF), a pivotal player in securities litigation. You’ve got to wonder what dirt might be uncovered here,...

Breakthrough T1D Pushes Global T1D Awareness Forward

Shining a Light on T1D with Global Efforts In a world where a change in lifestyle can happen at the drop of a hat, Breakthrough T1D is making waves by expanding their global "See T1D" campaign in honor of World Diabetes Day. This isn't your run-of-the-mill awareness push—this is about propelling an understanding of what life truly entails for those living with type 1...

Greenberg Traurig's Brad Kaufman: A Mentor of Resolute Impact

A Milestone for Mentorship at Greenberg Traurig In the often cutthroat jungle of law, finding someone who actually gives a damn about you is as rare as finding a unicorn. Yet, there it is—Brad Kaufman, at the helm of Greenberg Traurig's professional development, proving that mentorship can be more than just a checkbox on a quarterly review. Award for Exceptional...

Fluence Energy Faces Leadership Departures Amid Legal Woes

Fluence Energy's Rocky Road Continues It's chaos once again in the halls of Fluence Energy (NASDAQ:FLNC). The ship seems to drift further from solid ground as their CEO and CFO candidly decided to jump ship, shaking investor confidence even more vigorously. The market's reaction was swift and brutal: a nasty 9% share drop, leaving investors with more than just a headache....

IEHP's Wellness Center Launch Faces Delay in California

Unexpected Delay for IEHP's Community Hub Straight outta Rancho Cucamonga, we've got some news that'll have folks in San Bernardino holding their breath a little longer. The Inland Empire Health Plan (or IEHP if you're part of the 1.4 million served by them) had folks pumped for their new Community Wellness Center. But guess what? They had to slam the brakes on the grand...

SmallRig Boosts Art-Driven Innovation in AI Era

The Interplay of Art and AI In a world where the lines between man and machine blur faster than ever, creators like SmallRig are boldly asking: what role should authenticity play when AI takes the stage? The Shenzhen International Art Museum and SmallRig stood shoulder to shoulder, tackling this head-scrambling question with a global gathering of art and tech giants. It's...

Beko Pushes for Policy Synergy Amidst Carbon Shakeup

When big names like Beko step up on the global stage, you pay attention. During the COP31 panels in Antalya, Türkiye, the company's brass made one thing clear: we need harmony in how climate, trade, and finance policies come together. The stakes? The very strength of industrial competitiveness as new carbon rules turn the heat up on manufacturing practices. The Call for...

CARsgen's CAR-T Breakthrough on China's Insurance List

A Game Changer for CAR-T Therapies There's a breeze of optimism blowing from Shanghai these days—a rare sensation in this market of endless skirmishes. CARsgen Therapeutics Holdings Limited, a company entrenched in the development of cutting-edge CAR T-cell therapies, just notched a victory. They've announced that their CAR T-cell therapy product, satricabtagene...

HONGQI's EHS4 Launch in Europe: Bridging East and West

Revving Up a New Chapter: HONGQI in Venice There's a new player in the European automotive scene, and it's rolling in with more style than a Venetian gondola. HONGQI, a name that's been turning gears in China since '58, is packing its suitcases full of Eastern elegance and landing straight in Venice with the all-electric EHS4. On November 16, the brand is set to unveil...

Novo's CagriSema Trial Shows Promising Obesity Results

Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...